1. MEDICAL CORRECTION OF DISORDERS OF URINATION AFTER THE TRANSURETHRAL RESECTION OF BENIGN PROSTATIC HYPERPLASIA. О.О. Stroy, А.V. Shulyak, Borys B. Yu., J.О. Mytsyk, V.V. Dmytrienko Lviv National Medical University named after Danylo Halysky

2. Introduction. According to autopsy data, BPH is found in 20% in the age group 40-50 years, in 40% of males in the age group 50-60 years. According to autopsy data, BPH is found in 20% in the age group 40-50 years, in 40% of males in the age group 50-60 years. There are over 100,000 BPH patients currently registered in Ukraine. There are over 100,000 BPH patients currently registered in Ukraine. up to 70% - in 60-70 year-olds and 80% in the population of 70-80 years. up to 70% - in 60-70 year-olds and 80% in the population of 70-80 years. The appearance of disuric symptoms after TURP in the immediate postoperative period is primarily related to inflammation and edema in the traumatized tissues. The appearance of disuric symptoms after TURP in the immediate postoperative period is primarily related to inflammation and edema in the traumatized tissues. Taking into consideration the fact that in many instances the hyperplasic prostatic tissue is not entirely removed one of the main reason of postoperative disorders of urination becomes clear. Taking into consideration the fact that in many instances the hyperplasic prostatic tissue is not entirely removed one of the main reason of postoperative disorders of urination becomes clear.

3. Objectives. The research purpose was to explore efficiency of the combined medical correction of disorders of urination in patients with BPH after transurethral resection. The research purpose was to explore efficiency of the combined medical correction of disorders of urination in patients with BPH after transurethral resection.

4. Materials and methods. During research 95 patients were studied (main group) with BPH, in whom operating treatment was preformed the transurethral resection of BPH. During research 95 patients were studied (main group) with BPH, in whom operating treatment was preformed the transurethral resection of BPH. The following treatment was appointed in this group: a-1- adrenoblocker “Setegys” (Terazozine) 2 mg once a day and herbal formula “Bodyprost” 1 tsp b.i.d. with meals. The treatment was initiated on 4-6 day after surgery (after removal of the indwelling catheter) and lasted for a total of 4 weeks. The following treatment was appointed in this group: a-1- adrenoblocker “Setegys” (Terazozine) 2 mg once a day and herbal formula “Bodyprost” 1 tsp b.i.d. with meals. The treatment was initiated on 4-6 day after surgery (after removal of the indwelling catheter) and lasted for a total of 4 weeks. In order to compare treatment efficacy the control group was created in which placebo was administered. The control group included 93 patients with BPH, in whom transurethral resection was performed as well. In order to compare treatment efficacy the control group was created in which placebo was administered. The control group included 93 patients with BPH, in whom transurethral resection was performed as well.

5. The results of treatment were evaluated using the I-PSS symptom score, ultrasonography, prostatic secretions composition, biochemical and clinical analyses of blood and urine, urodynamic studies. The results of treatment were evaluated using the I-PSS symptom score, ultrasonography, prostatic secretions composition, biochemical and clinical analyses of blood and urine, urodynamic studies. In the main group the assessment was performed before the treatment, on the 2-nd and on the 4-th week of treatment. In the control group the assessment was performed before treatment and on the 4-th week after the treatment. In the main group the assessment was performed before the treatment, on the 2-nd and on the 4-th week of treatment. In the control group the assessment was performed before treatment and on the 4-th week after the treatment. The age of patients in both groups ranged 48-87 years. Mean age of patients in the main group was 65,4±3,2 years, in the control group 64,8±3,4 years. The age of patients in both groups ranged 48-87 years. Mean age of patients in the main group was 65,4±3,2 years, in the control group 64,8±3,4 years. Materials and methods.

6. Results and their discussion. Changes of clinical presentation in main group.

7. Results and their discussion. Changes of clinical presentation in control group.

8. The same situation was observed in the functio- nal studies of urinary tract before and after treatment: The same situation was observed in the functio- nal studies of urinary tract before and after treatment: The changes of maximal urine flow volume (Qmax) in the main group was from 14,5±0,2 ml/sec to 16,3±0,3 ml/sec. The changes of maximal urine flow volume (Qmax) in the main group was from 14,5±0,2 ml/sec to 16,3±0,3 ml/sec. The changes of maximal urine flow volume in the control group was from 13,9±0,4 ml/sec to 14,6±0,2 ml/sec. The changes of maximal urine flow volume in the control group was from 13,9±0,4 ml/sec to 14,6±0,2 ml/sec. Results and their discussion.

9. Conclusions: There was a positive therapeutic effect obtained in the main group compared the control one which speaks of the efficacy of combined medical therapy of disuric conditions in patients with benign prostatic hyperplasia of Stage II after transurethral resection which allows to decrease the appearance of disuric complications in the early postoperative period. There was a positive therapeutic effect obtained in the main group compared the control one which speaks of the efficacy of combined medical therapy of disuric conditions in patients with benign prostatic hyperplasia of Stage II after transurethral resection which allows to decrease the appearance of disuric complications in the early postoperative period. The proposed medical therapy has not caused any serious adverse effects in patients, which demonstrated a high safety profile and possibility of usage by patients with co-morbidities. The proposed medical therapy has not caused any serious adverse effects in patients, which demonstrated a high safety profile and possibility of usage by patients with co-morbidities.

10. Thank you for attention!